Compare CDMOs with cardiovascular drug manufacturing expertise for antihypertensives, anticoagulants, antiarrhythmics, and lipid-lowering therapies. Filter by dosage form, scale, and regulatory approvals.
171 companies listed
Cardiovascular drugs represent one of the largest established therapeutic segments, with a mature generics market and growing biologics pipeline. Manufacturing spans small molecule APIs (statins, ACE inhibitors, beta-blockers, calcium channel blockers), controlled-release oral solid dosage forms, and an expanding portfolio of injectable biologics (PCSK9 inhibitors, anti-inflammatory antibodies for atherosclerosis).
Formulation complexity is increasing. Many cardiovascular drugs require modified-release profiles to maintain therapeutic levels over 24 hours with once-daily dosing. Fixed-dose combinations (e.g., statin + antihypertensive) add formulation challenges around drug-drug compatibility, stability, and dissolution profile matching. CDMOs with strong oral solid dose and coating capabilities are well positioned.
Scale matters in this segment. Cardiovascular drugs often reach blockbuster commercial volumes -- hundreds of millions of doses per year. CDMOs need high-throughput tableting lines, efficient coating systems, and robust supply chain management to handle these volumes reliably. Ask about batch success rates and on-time delivery metrics for commercial-scale programs.
India
Kaisha Lifesciences is a pharmaceutical company under the Dadachanji Group of Companies (30+ year heritage), offering contract R&D services from product development to scale-up, plus its own product portfolio. Part of a diversified group including Schott Kaisha (glass vials, 50% acquired by Serum Institute of India), Kaisha Packaging, and Kaisha Medisurge. WHO-GMP certified manufacturing facility for terminally sterilized and aseptically filled injectables in ampoules, vials (liquid and lyophilized), and pre-filled syringes. Departments include formulation development, analytical development, quality assurance, and regulatory affairs. Products include Enoxaparin Sodium Injection. First Indian patent approval 2021.
Germany
KD Pharma Group is a pure-play, technology-driven CDMO with unique expertise in lipids (omega-3 APIs from fish and algae) and specialized small molecule products. Offers vertically integrated services: API manufacturing (lipid-based and small molecule), finished dosage forms (softgels, liquid bottling, packaging). Pharma division (KD Pharma) provides pharmaceutical APIs and custom synthesis. Nutra division (KD Nutra) serves nutritional supplement companies. KD Biopharma runs Phase 3 clinical trials for lipid-based therapeutics (FAP, UC, COVID-19). Recently expanded manufacturing site in Seal Sands, UK. FDA registered with 2 FEI numbers, 3 inspections (3 VAI).
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.